Serum high mobility group box‐1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma
- 30 July 2012
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 103 (9), 1714-1721
- https://doi.org/10.1111/j.1349-7006.2012.02358.x
Abstract
Extracellular high mobility group box-1 (HMGB1) contributes to tumor growth and invasiveness. We evaluated the diagnostic and prognostic ability of serum HMGB1 for pancreatic ductal adenocarcinoma (PDAC). Serum HMGB1 measured by enzyme-linked immunosorbent assay (ELISA) were compared among normal, chronic pancreatitis, PDAC group in both training (n similar to=similar to 25, each group) and independent validation set (n similar to=similar to 45, each group). To determine the usability of serum HMGB1 as a diagnostic predictor of PDAC, receiver operating characteristic (ROC) curves with sensitivity/specificity and logistic regression were evaluated. To assess the HMGB1-associated prognosis of PDAC, KaplanMeier survival and Cox proportional-hazards regression were applied. Serum HMGB1 was correlated with presence and advanced-stage of PDAC. Logistic regression exhibited serum HMGB1 was a remarkable biomarker to predict PDAC as a single or multiple-markers; sensitivity/specificity of serum HMGB1 were superior to carbohydrate antigen (CA) 19-9 or carcinoembryonic antigen (CEA) in both training and independent datasets. KaplanMeier survival analysis showed PDAC patients with high serum HMGB1 levels (>30 similar to ng/mL; median survival, 192 similar to days) had a worse prognosis than patients with low HMGB1 levels (=30 similar to ng/mL; 514 similar to days) by log-rank (P similar to=similar to 0.017). Cox proportional-hazards model showed the relative hazard ratios in high-serum HMGB1 group was 3.077 compared with the low-serum HMGB1 group. In conclusion, serum HMGB1 is a desirable diagnostic and prognostic biomarker for PDAC compared with pre-existing PDAC biomarkers, CA19-9 and CEA.Keywords
This publication has 27 references indexed in Scilit:
- High-mobility group box 1 and cancerBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2010
- Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinomaZeitschrift für Krebsforschung und Klinische Onkologie, 2009
- Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancerJournal of Translational Medicine, 2009
- Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinomaThe Journal of Pathology, 2008
- Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-κB activationThe Journal of cell biology, 2007
- High Mobility Group Box I (HMGB1) Release From Tumor Cells After Treatment: Implications for Development of Targeted ChemoimmunotherapyJournal of Immunotherapy, 2007
- Masquerader: High Mobility Group Box-1 and CancerClinical Cancer Research, 2007
- Angiogenetic Signaling through Hypoxia: HMGB1: An Angiogenetic Switch MoleculeThe American Journal of Pathology, 2005
- Towards Complete and Accurate Reporting of Studies of Diagnostic Accuracy: The STARD InitiativeClinical Chemistry, 2003
- Pancreatic CarcinomaNew England Journal of Medicine, 1992